Diagnostic Accuracy of M3 in Predicting Colorectal Advanced Adenoma Recurrence (M3-AA)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorChinese University of Hong Kong
About this trial
The investigators aim to evaluate the diagnostic accuracy of FIT and the novel panel of four bacterial gene markers collectively named as M3, to detect recurrent advanced adenomas in patients with history of colonic adenomas.
Eligibility criteria
Qualifiers
Known colorectal adenomas during index colonoscopy;
Available baseline M3 and FIT results before index colonoscopy;
Aged ≥18 years old;
Written informed consent obtained.
Disqualifiers
Refusal or unfit to undergo surveillance colonoscopy;
Incomplete colonoscopy, incomplete removal of colorectal adenomas, or inadequate bowel preparation (defined as Boston Bowel Preparation Scale score 0 or 1 in any colonic segment) at index colonoscopy;
Previous colonic resection;
Personal history of colorectal cancer;
Trial design
Treatments tested in this trial
- M3
- FIT
Treatment groups
600 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov